Loading organizations...
Key people at Gameloch Biotech.
Based in New York City, Gameloch Biotech is a biotechnology company developing stem cell-derived therapies for women's reproductive health, including infertility and menopause treatments. The firm engineers ovarian support cells to improve in vitro fertilization outcomes and is currently advancing its lead clinical program, Fertilo, into Phase 3 trials. The enterprise has raised approximately $127 million in total funding to date, which includes $117 million in venture capital and a recent $10 million award. Gameloch Biotech is backed by prominent entities, securing grants from ARPA-H and building on foundational research from the laboratory of geneticist George Church. The company also maintains strategic ties to the broader fertility sector through associations with organizations like Prelude Fertility and Overture Life. Gameloch Biotech was founded around 2021 by Dina Turner, Christian Kramme, Gus Haddad, and Martin Varsavsky.
No verifiable information exists on a company named Gameloch Biotech. Searches returned details on Gameto, a Texas-based clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health, and unrelated entities like GPGIC, a multinational startup association focused on technology solutions.[1][2][3] Assuming the query refers to Gameto due to phonetic similarity and biotech context, it builds Fertilo, a lead program advancing to Phase III trials for reproductive health applications. Fertilo targets infertility issues, serving patients and clinics globally, with over 20 pregnancies and five babies born; it solves access barriers to advanced fertility treatments and is cleared for commercialization in countries including Peru, Mexico, Australia, Japan, India, Singapore, Guatemala, Argentina, and Paraguay.[1]
Gameto has raised $127 million total, including a recent $44 million Series C, fueling its push toward global regulatory approvals and clinical completion, signaling strong growth momentum in the reproductive biotech space.[1]
Details on Gameto's founders, exact founding year, or idea emergence are unavailable in search results. The company originated as a Texas, USA-based clinical-stage biotech focused on stem cell-derived therapies for reproductive health, progressing rapidly to advanced clinical stages with its Fertilo program already in use internationally.[1] Pivotal moments include achieving regulatory clearances in multiple countries and recording real-world outcomes like pregnancies and births, alongside securing $127 million in funding to reach Phase III completion.[1]
Gameto stands out in reproductive biotech through:
No data on developer experience, pricing, or community specifics.
Gameto rides the reproductive health biotech trend, leveraging stem cell therapies amid rising demand for fertility solutions driven by aging populations and advancing gene/cell tech. Timing aligns with regulatory progress in emerging markets, where clearances in Asia and Latin America capitalize on market forces like underserved fertility access.[1] It influences the ecosystem by pioneering curative-like treatments, accelerating industry validation for stem cell platforms in women's health.
Gameto's Series C positions it to wrap Phase III for Fertilo and pursue global approvals, potentially expanding U.S. commercialization. Trends like personalized reproductive therapies and international clinic adoption will shape its path, evolving its influence toward a leader in accessible fertility biotech. This builds on its funding momentum, mirroring the rapid clinical ascent that defines its promise.[1]
Key people at Gameloch Biotech.
